GSK and Sanofi report positive data from COVID-19 vaccine candidate trial: Strong immune responses seen in adults of all ages
Sanofi and GSK announced today that their COVID-19 vaccine candidate demonstrated strong immune responses across all adult age groups in a Phase 2 trial.